BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 07, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

CP-4126: Phase II started

Clovis began the open-label, U.S. Phase II CO-101-003 trial to evaluate 1,250 mg/m 2 IV CP-4126 weekly for the first 3 weeks of a 4-week cycle in 35 patients who are refractory to gemcitabine...

Read the full 150 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >